Key result
Human beta1-adrenergic receptor autoantibodies from patients with dilated cardiomyopathy potently stimulated ERK1/2 in murine cardiomyocytes via pathways distinct from classic beta-agonists.
Why the study?
Do beta1AR autoantibodies from DCM patients stimulate the ERK1/2 pathway in murine cardiomyocytes differently than classic beta-agonists?
Do beta1AR autoantibodies from DCM patients stimulate the ERK1/2 pathway in murine cardiomyocytes differently than classic beta-agonists?
Beta1AR autoantibodies from DCM patients activate ERK1/2 pathways in cardiomyocytes differently than classic beta-agonists, suggesting a distinct active receptor conformation that may contribute to heart failure pathogenesis.
Answers are grounded in this paper and cite their sources.
Distinct beta1AR autoantibody signaling may contribute to DCM pathogenesis; leaves open human relevance and therapeutic targeting.
OBJECTIVE: Antibodies specific for the beta1-adrenergic receptor (beta1AR) are highly prevalent in patients with idiopathic dilated cardiomyopathy (DCM) and known to contribute to the pathogenesis of heart failure, though the precise molecular mechanisms involved are largely unknown. METHODS: We have explored the effects of beta(1)AR autoantibodies obtained from DCM patients on extracellular signal-regulated kinase (ERK) activation in murine cardiomyocytes. RESULTS: We find that human beta(1)AR autoantibodies potently stimulate ERK1/2 in cardiac cells by using signalling pathways different from those triggered by the classic beta-agonist isoproterenol, also leading to a different pattern of activated ERK subcellular localization. The extent of ERK stimulation by endogenous cardiac beta(1)AR is markedly enhanced in the presence of both beta(1)AR-autoantibodies and isoproterenol. Interestingly, beta(1)AR-autoantibody-mediated ERK activation is not blocked by some betaAR antagonists used in the treatment of heart failure. CONCLUSIONS: Our results suggest that these antibodies elicit a distinct beta(1)AR active conformation that would lead to the engagement of signaling effectors different from those recruited by classic beta-agonists, a finding that could lead to better understanding of DCM pathogenesis and aid in designing diagnostic and therapeutic strategies.
No takes yet. Share an insight, caveat, or question.
Tutor et al. (2007) studied Idiopathic dilated cardiomyopathy (DCM). beta1-adrenergic receptor (beta1AR) autoantibodies vs. isoproterenol was evaluated on ERK1/2 activation in murine cardiomyocytes. Human beta1-adrenergic receptor autoantibodies from patients with dilated cardiomyopathy potently stimulated ERK1/2 in murine cardiomyocytes via pathways distinct from classic beta-agonists.
Synapse has enriched 10 related papers. Consider them for comparative context: